CMVIG Prophylaxis in Belatacept Conversion Kidney Transplant Recipients (NCT07096453)
CMVIG Prophylaxis in Belatacept Conversion Kidney Transplant Recipients: a PK Pilot Study
🩺 Plain-English Summary (8th-Grade Level)
The purpose of this study is to study how CMVIG interacts with the body and to see if it might work to prevent kidney transplant patients from becoming infected with CMV.
Who can join: To join this study, participants generally need to meet the listed inclusion criteria (4 items) and avoid the listed exclusions (6 items).
Location: University of Minnesota — Minneapolis, Minnesota
Age range: 18 Years to 70 Years
🧪 Interventions in This Study
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistCheck every box below. If you can check all of them, you may meet the study's basic screening requirements (final eligibility is confirmed by the site team).
Usually NOT eligible if any of the following apply:
- Exclusion Criteria:
- Pregnant people
- Subjects unwilling to sign consent and complete follow up visits
- Subjects with IgA immunodeficiency
- Subjects who are receiving IgG therapy or who have received IgG therapy within two months of study enrollment
- Patients who do not speak English and would need a translator and translated consent materials in order to obtain informed consent
🔍 Extracted verbatim from the official NIH eligibility criteria. Always confirm with the study coordinator.
📍 All Participating Trial Locations (1 Sites)
- University of Minnesota — Minneapolis, Minnesota
📞 Contact the Study Coordinator
Phone: (612) 624-9695
Email: surgcto@umn.edu
Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Kidney Transplant; Complications
- Pulse Wave Velocity, Tacrolimus Time in Therapeutic Range and CV in African American Kidney Transplants — Philadelphia, Pennsylvania
- Efficacy and Mechanisms of Dapagliflozin in Promoting Kidney Function and Cardiovascular Health in Kidney Transplant Recipients — Aurora, Colorado
- De-novo Initiation of Letermovir vs Valganciclovir for Cytomegalovirus Prophylaxis in AA Kidney Transplant Recipients — Richmond, Virginia
- Structured Program of Exercise for Recipients of Kidney Transplantation — San Francisco, California
- The EFfect of FinErenone in Kidney TransplantiOn Recipients: The EFFEKTOR Study — Chapel Hill, North Carolina
Explore by condition: All Kidney Transplant; Complications clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Contact the study coordinator using the phone/email above.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.